share_log

HC Wainwright & Co. Initiates Coverage On Zenas BioPharma With Buy Rating, Announces Price Target of $30

HC Wainwright & Co. Initiates Coverage On Zenas BioPharma With Buy Rating, Announces Price Target of $30

HC Wainwright & Co. 开始对Zenas BioPharma进行覆盖,给予买入评级,并宣布目标价为30美元。
Benzinga ·  12/16 07:28  · 评级/大行评级

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Zenas BioPharma (NASDAQ:ZBIO) with a Buy rating and announces Price Target of $30.

HC Wainwright & Co. 的分析师马修·考菲尔德开始关注Zenas BioPharma(纳斯达克:ZBIO),评级为买入,并宣布价格目标为30美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发